JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
Instituto de Investigación Sanitaria Gregorio Marañón
Madrid, EspañaPublicacions en col·laboració amb investigadors/es de Instituto de Investigación Sanitaria Gregorio Marañón (9)
2024
-
COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant
Cancers, Vol. 16, Núm. 2
-
Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study
Journal of Infection and Public Health, Vol. 17, Núm. 7
2023
-
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
Cancers, Vol. 15, Núm. 5
-
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study
Journal of Geriatric Oncology, Vol. 14, Núm. 1
2022
-
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
Biomarker Research, Vol. 10, Núm. 1
2021
-
Risk factors and mortality of COVID-19 in patients with lymphoma: A multicenter study
HemaSphere, Vol. 5, Núm. 3, pp. 1-8
2020
-
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study
Journal of Hematology and Oncology, Vol. 13, Núm. 1
-
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Blood Cancer Journal, Vol. 10, Núm. 10
2018
-
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098